Abstract: Provided are a novel carboxymethyl cellulose (CMC) structure and a method for producing the same. The CMC structure of the present invention is useful as a medical material and particularly as an adhesion-preventing material, and has good biocompatibility and bioabsorbability and controllable periods of functioning and dissolving, or has both effects for preventing adhesions and wound healing. The CMC structure of the present invention is substantially composed of carboxymethyl celluloses, comprising an acid carboxymethyl cellulose and an alkaline metal carboxymethyl cellulose in a mixed state. The method of production of the present invention comprises subjecting the alkaline metal (or acid) carboxymethyl cellulose structure to an acid (or alkali) treatment, wherein the acid (or alkali) treatment is terminated before the alkaline metal (or acid) carboxymethyl cellulose is fully converted to the acid (or alkaline metal) carboxymethyl cellulose.

Abstract: A hemostatic agent, an agent for promoting cellular adhesion and an agent for curing an injury, each comprising an alkali or alkali earth metal salt of carboxylmethyl cellulose, and a pharmaceutically acceptable carrier are disclosed.

Abstract: A hemostatic agent, an agent for promoting cellular adhesion and an agent for curing an injury, each comprising an alkali or alkali earth metal salt of carboxylmethyl cellulose, and a pharmaceutically acceptable carrier are disclosed.

Abstract: A hemostatic agent, an agent for promoting cellular adhesion and an agent for curing an injury, each comprising an alkali or alkali earth metal salt of carboxylmethyl cellulose, and a pharmaceutically acceptable carrier are disclosed.

Abstract: A hemostatic agent, an age for promoting cellular adhesion and an agent for curing an injury, each comprising an alkali or alkali earth metal salt of carboxylmethyl cellulose, and a pharmaceutically acceptable carrier are disclosed.

Abstract: A tissue sealant comprising thrombin, fibrinogen, and carboxylmethyl cellulose or an alkali metal or alkali earth metal salt thereof is disclosed. The tissue sealant of the present invention promotes a hemostasis of an injury to a skin surface or a viscus, a healing of an injury, an endothelium formation of a blood vessel, an adhesive activity of animal cells, such as endothelial cells or fibroblasts in vitro, and an adhesion and agglutination of platelets.

Abstract: A first monoclonal antibody which specifically reacts with a human .alpha..sub.2 -plasmin inhibitor complex (PIC) and a human plasminogen; a second monoclonal antibody which reacts with PIC and also with a human .alpha..sub.2 -plasmin inhibitor; a third monoclonal antibody which reacts with PIC, but does not react with a human plasminogen and a human .alpha..sub.2 -plasmin inhibitor; hybridomas which secrete the first to third monoclonal antibodies, and an immunoassay using the first to third monoclonal antibodies.

Abstract: A monoclonal antibody that reacts with a human soluble fibrin but not with a human fibrinogen; a hybridoma that secretes the above antibody; and a method of assaying a human soluble fibrin with the above antibody. It is possible to determine the amount of soluble fibrin in the plasma of a patient specifically, readily and rapidly by agglutination and EIA without being affected by plasma fibrinogen, plasmin-degradation product of fibrinogen, fibrin fragment, and plasmin-degradation product of stabilized fibrin even without pretreating the plasma sample.

Abstract: Monoclonal antibodies specifically reacting with the side face of a C-reactive protein (CRP), i.e., monoclonal antibodies specifically reacting with the side face of a disk-like subunit of a C-reactive protein (CRP), hybridoma producing the monoclonal antibody, and methods for the use thereof are disclosed.